Quicksearch

LEADER 04438pam a2200469 i 4500

001 14081204

005 20190501230144.0

008 180930t20192019enk b 001 0 eng c

010

|a 2018042746

020

|a 9781138500273 |q hardcover |q alkaline paper

020

|a 1138500275 |q hardcover |q alkaline paper

020

|z 9781351012713 |q electronic book

024

8

|a 99980184184

035

|a (NhCcYBP) 2018042746

035

|a 14081204

040

042

|a pcc

043

|a n-us---

050

0

|a HD9666 |b .K55 2019

090

|a HD9666 |b .K55 2019 (LC)

100

1

|a Kim, Rachel, |d 1970- |e author. |0 http://id.loc.gov/authorities/names/no2018138579

245

1

0

|a Economics and management in the biopharmaceutical industry in the USA : |b evolution and strategic change / |c Rachel Kim.

264

1

|a Abingdon, Oxon ; |a New York, NY : |b Routledge, |c 2019.

264

4

300

|a vii, 141 pages ; |c 25 cm.

336

|a text |b txt |2 rdacontent

337

|a unmediated |b n |2 rdamedia

338

|a volume |b nc |2 rdacarrier

490

1

|a Routledge studies in the economics of business and industry ; |v 4

504

|a Includes bibliographical references and index.

520

|a "From a managerial perspective, the biopharmaceutical industry represents a competitive, fast-changing, intellectually-powered, innovation-driven sector. Many management scholars have studied this discontinuous era to make sense of strategic behavior and the cognition of firms and top managers. A past look at the biopharmaceutical industry provides answers to questions that most managers have. For example, what options do you have and what actions do you take when new firms enter your industry? In the 1970s, new biotechnology firms, funded by venture capitalists, appeared in the pharmaceutical industry with new knowledge. Successful pharmaceutical firms decided to collaborate with the new entrants and forge relationships to develop and create new, biotechnology engineered drugs. Thus, the addition of new biotechnology firms ushered in a new business model based on strategic alliances. Strategic alliances have now become an industrial norm called open innovation. The author looks at the historical path of the biopharmaceutical industry, particularly in the United States. While the pharmaceutical industry's main contributions to society are substantial, there are pressing challenges the industry must face, such as an increase in infectious disease outbreaks or the global aging population, which require new types of care, additionally, mental health care and prescription painkiller addiction are persistent issues with economic repercussions to both federal and local governments. This book presents a holistic view of the biopharmaceutical industry, putting it in a historical context. It will best serve those eager to learn about this dynamic, fast-evolving industry"-- |c Provided by publisher.

505

0

|a Overview of strategic management and corporate practice in the U.S. -- Introduction -- In early days of pharmaceutical industry worldwide -- The birth of biotechnology -- Emergence of biotechnology firms in 1970s & 1990s -- New biotechnology firms emergence from pharmaceutical management perspective -- U.S. regulations on biopharmaceutical industry and their impact -- Law & strategies: how biopharma's strategies adapted in response to U.S. law changes -- Opportunistic business models is the generic drug market -- Low productivity of drug companies -- Payers, purchasers, & promotions -- Innovation capabilities -- Immuno-cancer therapy -- Biopharmaceutical industry in the future.

650

0

|a Pharmaceutical biotechnology industry |z United States |x History.

650

0

|a Pharmaceutical biotechnology |z United States |x History.

776

0

8

830

0

|a Routledge studies in the economics of business and industry ; |v 4. |0 http://id.loc.gov/authorities/names/no2017107234

901

|a HD9666

902

|a Sterling Memorial Library |b SML, Stacks, LC Classification >> HD9666 .K55 2019 (LC)|DELIM|14088126

907

|a 2019-05-13T11:57:33.000Z

960

|a 39002134898171 |o 1 |s 119.72 |t sml |u YBSMSOC151

961

|c 190429 |f 11605 |m 653111

987

|c ON ORDER

Librarian View